ticagrelor for Coronary Artery Disease

Phase-Based Estimates
1
Effectiveness
2
Safety
Endothelial Function detection by brachial artery ultrasound, Harbin, China
Coronary Artery Disease+2 More
ticagrelor - Drug
Eligibility
18+
All Sexes
Eligible conditions
Coronary Artery Disease

Study Summary

This study is evaluating whether a low dose of ticagrelor is superior to clopidogrel in diabetic patients with stable coronary artery disease.

See full description

Eligible Conditions

  • Coronary Artery Disease
  • Coronary Disease
  • Myocardial Ischemia

Treatment Effectiveness

Study Objectives

This trial is evaluating whether ticagrelor will improve 1 primary outcome and 1 secondary outcome in patients with Coronary Artery Disease. Measurement will happen over the course of up to 1 month.

up to 1 month
Endothelial Function
Inhibition of platelet aggregation

Trial Safety

Safety Estimate

2 of 3
This is better than 68% of similar trials

Side Effects for

Aspirin + Ticagrelor
BARC 235
7%
Myocardial Infarction
3%
Stent Thrombosis, definite or probable
1%
Ischemic Stroke
0%
This histogram enumerates side effects from a completed 2019 Phase 4 trial (NCT02270242) in the Aspirin + Ticagrelor ARM group. Side effects include: BARC 235 with 7%, Myocardial Infarction with 3%, Stent Thrombosis, definite or probable with 1%, Ischemic Stroke with 0%.

Trial Design

4 Treatment Groups

Clopidogrel
Ticagrelor 90 mg

This trial requires 60 total participants across 4 different treatment groups

This trial involves 4 different treatments. Ticagrelor is the primary treatment being studied. Participants will be divided into 3 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 & 3 and have had some early promising results.

Ticagrelor 90 mg
Drug
Ticagrelor (90 mg, twice daily, oral) treatment for 1 month.
Ticagrelor 22.5 mg
Drug
Ticagrelor (22.5 mg, twice daily, oral) treatment for 1 month.
Ticagrelor 45 mg
Drug
Ticagrelor (45 mg, twice daily, oral) treatment for 1 month.
Clopidogrel
Drug
Clopidogrel (75mg, once daily, oral) treatment for 1 month.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ticagrelor
FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 1 month
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly up to 1 month for reporting.

Closest Location

VerifyNow - San Diego, CA

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 2 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
(1) Patients who have stable coronary artery disease and angina symptoms are classified as having "stable angina." (2) Patients who have unstable angina and a low risk of death or heart attack are classified as having "low-risk unstable angina." (3) Patients who have unstable angina and a higher risk of death or heart attack are classified as having "variant angina." (4) Patients who have asymptomatic coronary artery disease and are being treated with appropriate therapies, including percutaneous coronary intervention (PCI), are classified as having "appropriate therapy. show original
Diabetes

Patient Q&A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can coronary artery disease be cured?

Add answer

Coronary artery disease is associated with increased cardiovascular mortality. Patients with coronary artery disease may also suffer from disability and reduction of quality of life. The most frequent cause of death in patients with coronary artery disease belongs to recurrent coronary artery occlusion and complications of treatment, and these results depend greatly on the presence of concomitant peripheral vascular disease.

Unverified Answer

What causes coronary artery disease?

Add answer

Atherosclerosis and heart artery disease can be due to a combination of the many genetic and environmental factors. There may also exist specific diseases such as the systemic amyloidosis and systemic lupus erythematosus, or diseases of heredity, or acquired factors such as smoking and diabetes. It is likely that it is caused by some factor of which there are many potential contributors.

Unverified Answer

What are common treatments for coronary artery disease?

Add answer

Treatment options for coronary artery disease include a variety of different treatments. Typically, coronary artery disease is treated with a statin or drugs that lower cholesterol. Surgery is often recommended when people have severe problems with the blood vessels and other major organs. A number of coronary intervention techniques are available, including percutaneous coronary intervention (coronary angioplasty) and coronary artery bypass graft (possible graft placement) surgery. Many coronary artery diseases can be treated with medication(s) rather than surgery. Sometimes there is a combination of the two treatments in which case surgery is a part of the treatment plan.

Unverified Answer

How many people get coronary artery disease a year in the United States?

Add answer

Overall, approximately 32.1 million Americans are affected, and around 29.8% of these people have coronary artery disease. This makes it the most common cause of heart attacks and sudden cardiac death.

Unverified Answer

What are the signs of coronary artery disease?

Add answer

Coronary artery disease involves symptoms such as shortness of breath and chest pain. These may lead to the need for medications such as aspirin for low-risk individuals.\n

Unverified Answer

What is coronary artery disease?

Add answer

CAD is an important health condition that is associated with an increased risk of mortality in a population, especially on men of advanced age. However, the incidence of CAD in population is not sufficient to justify its treatment in population without comorbidities associated with more serious CAD.

Unverified Answer

What are the latest developments in ticagrelor for therapeutic use?

Add answer

Ticagrelor (as opposed to placebo or clopidogrel alone), like prasugrel, has proven effective in lowering the risk of thromboembolic events in patients with stable coronary artery disease (CAD) receiving percutaneous coronary intervention (PCI). The efficacy of ticagrelor appears to be similar to that of prasugrel to date. This promising benefit and excellent oral bioavailability makes ticagrelor a good option for this patient group.

Unverified Answer

Who should consider clinical trials for coronary artery disease?

Add answer

Clinical trial recruitment depends, in part, on whether the study may change the standard of care. Those trials with limited expected effect are likely to attract few participants.

Unverified Answer

Does coronary artery disease run in families?

Add answer

Although the prevalence of CAD in families of coronary cases exceeds that (50%) generally observed in case-ascertainment studies of family members of individuals with proven CAD, this does not imply that members of coronary families have an increased risk of CAD.

Unverified Answer

Have there been other clinical trials involving ticagrelor?

Add answer

Only 2 have conducted ticagrelor clinical trials on patients admitted after a myocardial infarction, with the results presented in 2 publications. Only one of them has included an estimation of the sample size that needs to be recruited for the trial in order to detect a clinically relevant clinical effect. This may affect the number of treatments that can be evaluated in patients admitted for treatment after an myocardial infarction. The trial in the published study, which included 944 patients in 749 days, indicated an 18% reduction in the risk of 1-year death if patients were prescribed ticagrelor compared to patients who were prescribed clopidogrel.

Unverified Answer

Has ticagrelor proven to be more effective than a placebo?

Add answer

The new oral P2Y(12) receptor inhibitor ticagrelor was effective, and had a higher rate of thromboprophylaxis than placebo during dual antiplatelet therapy for patients undergoing carotid endarterectomy.

Unverified Answer

What is the primary cause of coronary artery disease?

Add answer

A significant proportion of patients die prior to the occurrence of coronary artery disease; therefore, it is highly important to understand how this pathophysiology may affect health and modify disease risk.

Unverified Answer
See if you qualify for this trial
Get access to this novel treatment for Coronary Artery Disease by sharing your contact details with the study coordinator.